Summary and expectation of the role of GnRHa in the treatment of breast cancer
10.3760/cma.j.issn.0253-3766.2019.04.002
- VernacularTitle: 促性腺激素释放激素类似物在乳腺癌治疗中的应用及前景
- Author:
Xiaolin LI
1
;
Yang YU
2
;
Xiangyun ZONG
1
Author Information
1. Department of Breast Surgery, Shanghai Jiao Tong University affiliated Shanghai Sixth People′s Hospital, Shanghai 200233, China
2. Department of Breast Surgery, Zhejiang Cancer Hospital, Hangzhou 310022, China
- Publication Type:Review
- Keywords:
Breast neoplasms;
GnRHa;
Adjuvant endocrine therapy;
Ovarian function;
Breast density
- From:
Chinese Journal of Oncology
2019;41(4):246-250
- CountryChina
- Language:Chinese
-
Abstract:
Gonadotropin-releasing-hormone analogues (GnRHa) are widely used in the treatment of premenopausal breast cancer. The anti-tumor effect of GnRHa is similar to that of surgical castration or chemotherapy, through reversibly inhibiting ovarian function and downregulating the estrogen level in premenopausal female. At the same time, GnRHa can protect the ovarian function, avoiding premature ovarian failure. Also GnRHa can reduce the breast density and endometrial thickness, as a result of which GnRHa may be used to prevent breast cancer in the higher risk population and promote quality of life in breast cancer patients. We here review the clinical roles and research progress of GnRHa in breast cancer.
